Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

BioTime, Inc. Announces Proposed Public Offering of Common Stock

Business Wire June 15, 2016

BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD

Business Wire June 13, 2016

BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

Business Wire June 10, 2016

BioTime to Present at the Jefferies 2016 Global Healthcare Conference

Business Wire June 9, 2016

BioTime to Present at Two Upcoming Investor Conferences

Business Wire May 20, 2016

BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments

Business Wire May 10, 2016

BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference

Business Wire April 26, 2016

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of Medical, Research, and Commercial Partners

Business Wire April 25, 2016

BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK

Business Wire April 5, 2016

BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016

Business Wire March 21, 2016

Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer

PR Newswire February 29, 2016

BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia

Business Wire February 24, 2016

BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents

Press Releases February 16, 2016

BioTime, Inc. to Present at Three Investor Conferences in February

Business Wire February 1, 2016

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

Business Wire January 12, 2016

OncoCyte Corporation Initiates Trading on the NYSE MKT

GlobeNewswire January 4, 2016

BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock

Business Wire December 31, 2015

BioTime Announces "When-Issued" Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution

Business Wire December 30, 2015

OncoCyte Appoints Dr. Andrew J. Last to Its Board of Directors

Business Wire December 23, 2015

Stephen C. Farrell Appointed to STAAR Surgical Board of Directors

PR Newswire December 17, 2015